

BBSRC and its predecessor AFRC have supported PI3-kinase research at Babraham since the late 1980s. This is leading to new therapies for various cancers, immune-deficiency and inflammation.

1. 0, ... 3- ...

IMPACT SUMMARY

BBSRC and its predecessor AFRC have supported PI3-kinase research at Babraham since the late 1980s. This is leading to new therapies for various cancers, immune-deficiency and inflammation.


Babraham scientists:

- are advising GSK on sample collection and analysis for a clinical trial, using novel mass spectrometry methods developed at Babraham.
- are working with clinicians to understand and develop treatments for various diseases caused by PI3-kinase mutations.
- received funding from US biotechnology company Icos Corporation for mouse genetics research. A drug to treat chronic lymphocytic leukaemia, discovered by Icos Corp., has recently completed

THE BABRAHAM INSTITUTE

T. B. I., B. R. C. UK, BBSRC.

I 2013/14 B I 28.8M² BBSRC, I S. P. G (ISPG) C. G (CCG), T. ISPG CCG BBSRC.



$\frac{1}{2} \times \frac{1}{3} = \frac{1}{6}$

$\frac{1}{2} \times \frac{1}{3} = \frac{1}{6}$

